PL411230A1 - DNA vaccine directed against the flue H5N1 virus, modified nucleotide sequence and application of the modified nucleotide sequence for production of the vaccine - Google Patents

DNA vaccine directed against the flue H5N1 virus, modified nucleotide sequence and application of the modified nucleotide sequence for production of the vaccine

Info

Publication number
PL411230A1
PL411230A1 PL411230A PL41123015A PL411230A1 PL 411230 A1 PL411230 A1 PL 411230A1 PL 411230 A PL411230 A PL 411230A PL 41123015 A PL41123015 A PL 41123015A PL 411230 A1 PL411230 A1 PL 411230A1
Authority
PL
Poland
Prior art keywords
nucleotide sequence
modified nucleotide
vaccine
production
directed against
Prior art date
Application number
PL411230A
Other languages
Polish (pl)
Other versions
PL229124B1 (en
Inventor
Włodzimierz Wiktor Zagórski-Ostoja
Agnieszka Sirko
Anna Góra-Sochacka
Grzegorz Kudla
Anna Stachyra
Patrycja Redkiewicz
Original Assignee
Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biochemii I Biofizyki Polskiej Akademii Nauk filed Critical Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Priority to PL411230A priority Critical patent/PL229124B1/en
Priority to PCT/PL2015/000096 priority patent/WO2016130031A1/en
Publication of PL411230A1 publication Critical patent/PL411230A1/en
Publication of PL229124B1 publication Critical patent/PL229124B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Przedmiotem wynalazku są: szczepionka DNA skierowana przeciwko wirusowi grypy H5N1, zmodyfikowana sekwencja nukleotydowa oraz zastosowanie zmodyfikowanej nukleotydowej sekwencji do wytwarzania szczepionki. Bardziej szczegółowo rozwiązanie dotyczy zastosowania modyfikacji sekwencji kodującej antygen w celu podwyższenia efektywności szczepionki DNA.The present invention relates to: a DNA vaccine directed against the H5N1 influenza virus, a modified nucleotide sequence and the use of a modified nucleotide sequence for the production of a vaccine. More specifically, the solution relates to the use of modification of the antigen coding sequence to increase the efficiency of the DNA vaccine.

PL411230A 2015-02-10 2015-02-10 DNA vaccine directed against the flue H5N1 virus, modified nucleotide sequence and application of the modified nucleotide sequence for production of the vaccine PL229124B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL411230A PL229124B1 (en) 2015-02-10 2015-02-10 DNA vaccine directed against the flue H5N1 virus, modified nucleotide sequence and application of the modified nucleotide sequence for production of the vaccine
PCT/PL2015/000096 WO2016130031A1 (en) 2015-02-10 2015-06-17 Dna vaccine against h5n1 influenza virus, modified nucleotide sequence and use of the modified nucleotide sequence in vaccine manufacturing

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL411230A PL229124B1 (en) 2015-02-10 2015-02-10 DNA vaccine directed against the flue H5N1 virus, modified nucleotide sequence and application of the modified nucleotide sequence for production of the vaccine

Publications (2)

Publication Number Publication Date
PL411230A1 true PL411230A1 (en) 2016-08-16
PL229124B1 PL229124B1 (en) 2018-06-29

Family

ID=53761465

Family Applications (1)

Application Number Title Priority Date Filing Date
PL411230A PL229124B1 (en) 2015-02-10 2015-02-10 DNA vaccine directed against the flue H5N1 virus, modified nucleotide sequence and application of the modified nucleotide sequence for production of the vaccine

Country Status (2)

Country Link
PL (1) PL229124B1 (en)
WO (1) WO2016130031A1 (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US20030096778A1 (en) 2002-06-13 2003-05-22 Shiver John W Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
EP1242441A4 (en) 1999-12-17 2004-04-14 Merck & Co Inc Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
US7078507B2 (en) 2001-11-09 2006-07-18 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Synthetic genes for malarial proteins and methods of use
US8383797B2 (en) 2005-11-16 2013-02-26 Toyo Boseki Kabushiki Kaisha Luciferase gene optimized for use in imaging of intracellular luminescence
WO2008124331A1 (en) 2007-04-03 2008-10-16 Cytogenix, Inc. Novel sequences and dna vaccines against avian flu
MX2009013008A (en) 2007-05-31 2010-06-09 Influenza vaccines.
WO2009092038A1 (en) 2008-01-16 2009-07-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza dna vaccination and methods of use thereof
DK2414386T3 (en) * 2009-04-03 2016-02-22 Merial Ltd Birds of vaccines with newcastle disease virus vectors
PL220281B1 (en) * 2011-09-23 2015-09-30 Inst Biochemii I Biofizyki Polskiej Akademii Nauk DNA vaccine, the method of inducing an immune response, the antibody specifically recognizing the protein of the influenza virus hemagglutinin H5 and the use of DNA vaccine
CN103589738B (en) * 2013-11-12 2015-08-26 中国疾病预防控制中心病毒病预防控制所 The transformation of HIV-1 Chinese epidemic strain CRF01_AE env gene

Also Published As

Publication number Publication date
PL229124B1 (en) 2018-06-29
WO2016130031A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
CL2019002196A1 (en) Neutralizing human antibodies that bind to influenza a hemagglutinin. (divisional application 201701610)
CY1125029T1 (en) MODIFIED NUCLEOSITES, NUCLEOTIDES, AND NUCLEIC ACIDS AND USES THEREOF
BR112018008078A2 (en) broad spectrum influenza virus vaccine
EA201891000A1 (en) VACCINE AGAINST RESPIRATORY-SYNCTIAL VIRUS
EA201890999A1 (en) VACCINE AGAINST VIRUS HERPES VIRUS
EA201891338A1 (en) COMPOSITIONS AND METHODS FOR IMMUNICOLOGY
MD3718565T2 (en) Respiratory virus vaccines
EA201692467A1 (en) VACCINES AGAINST FLU VIRUS AND THEIR USE
EA201691945A1 (en) ANTIBODIES TO HEMAGGLUTININ VIRUS OF TYPE B VIRUS AND METHODS OF THEIR APPLICATION
EA201692535A1 (en) SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND THEIR ANALOGUES
EA201591164A1 (en) VACCINES AGAINST FLU VIRUS AND THEIR USE
EA201790266A1 (en) INDOLS FOR USE IN INFECTIONS CAUSED BY THE FLU VIRUS
EA201890527A1 (en) THERAPEUTIC VACCINES AGAINST HPV18
MX2019007921A (en) Novel ha binding agents.
BR112015021880A2 (en) influenza b virus rearrangement
MX2021010060A (en) Production of viruses in avian eggs.
CY1123078T1 (en) IMPROVED METHODS FOR INDIVIDUAL POLIO VIRUS ADSORPTION
EA201692541A1 (en) VACCINES AGAINST FLU VIRUS AND THEIR USE
EA201890322A1 (en) NEW TOBAMOVIRUS TYPE
MX2017016896A (en) Inactivated canine influenza vaccines and methods of making and uses thereof.
BR112015012380A2 (en) recombinant influenza virus
PL408649A1 (en) Influenza viruses haemagglutinin protein as the vaccine antigen
EA201300525A1 (en) NEW VACCINES AGAINST PANDEMIC A / H1N1 FLU VIRUS
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
MX363464B (en) Influenza h5 vaccines.